PDF(Pubmed)
Abstract：
Although most differentiated thyroid carcinoma has a clinically favorable prognosis, some of specific types of thyroid cancer (such as anaplastic thyroid carcinoma and advanced papillary thyroid carcinoma) show fatal outcomes and require novel treatments. Immunotherapy is a promising avenue for the treatment of advanced thyroid carcinoma. B7-H3 (B7 homolog 3 protein) and ICAM-1 (intercellular adhesion molecule 1), as two important immune checkpoints (ICPs), is becoming hopeful target spots for immunotherapy. A growing amount of evidence has suggested that B7-H3 and ICAM-1 are upregulated in papillary thyroid carcinoma. However, their expression level in specific types of thyroid cancer remains largely unclear. In the present study, we explored the expression level of B7-H3 and ICAM-1 in different types of thyroid carcinoma. In the groups of the TCGA cohort, both B7-H3 and ICAM-1 mRNA were highly expressed in thyroid carcinoma. Furthermore, the patients with Stage2, 61-80y, Follicular thyroid papillary carcinoma and N0 had lower B7-H3 and ICAM-1 mRNA expression. In the groups of our cohort, PTCs and ATCs showed frequently moderate to strong expression of B7-H3 and ICAM-1 protein expression. The significant relevance of B7-H3 staining score with ICAM-1 staining score was observed in TCGA database and our cohort, which might open avenues for the combination therapy in advanced thyroid cancer.
摘要：
尽管大多数分化型甲状腺癌具有良好的临床预后，某些特定类型的甲状腺癌(如间变性甲状腺癌和晚期甲状腺乳头状癌)显示出致命的结局,需要新的治疗方法.免疫治疗是治疗晚期甲状腺癌的有希望的途径。B7-H3（B7同源物3蛋白）和ICAM-1（细胞间粘附分子1），作为两个重要的免疫检查点(ICPs)，正在成为免疫疗法的有希望的靶点。越来越多的证据表明B7-H3和ICAM-1在甲状腺乳头状癌中上调。然而,它们在特定类型甲状腺癌中的表达水平尚不清楚.在本研究中,我们探讨了B7-H3和ICAM-1在不同类型甲状腺癌中的表达水平。在TCGA队列的组中，B7-H3和ICAM-1mRNA在甲状腺癌中均高表达.此外，第2阶段的患者，61-80岁，滤泡性甲状腺乳头状癌和N0的B7-H3和ICAM-1mRNA表达较低。在我们队列的组中，PTC和ATC经常显示B7-H3和ICAM-1蛋白表达的中度至强表达。在TCGA数据库和我们的队列中观察到B7-H3染色评分与ICAM-1染色评分的显著相关性,这可能为晚期甲状腺癌的联合治疗开辟了道路。
